Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (LLY)
NYSE:LLY
Holding LLY?
Track your performance easily
LLY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$561.65 - $972.53
Previous Close$748.01
Volume4.02M
Average Volume (3M)3.44M
Market Cap
$710.10B
Enterprise Value$737.78B
Total Cash (Recent Filing)$3.52B
Total Debt (Recent Filing)$31.12B
Price to Earnings (P/E)81.8
Beta0.67
Next Earnings
Jan 30, 2025EPS Estimate
$5.47Last Dividend Ex-Date
Nov 15, 2024Dividend Yield0.67%
Share Statistics
EPS (TTM)9.14
Shares Outstanding949,315,694
10 Day Avg. Volume5,298,745
30 Day Avg. Volume3,441,645
Standard Deviation0.09
R-Squared0.06
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)50.23
Price to Sales (P/S)16.95
Price to Cash Flow (P/CF)46.70
P/FCF Ratio73.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue18.05
Enterprise Value/Gross Profit27.28
Enterprise Value/Ebitda59.88
Forecast
1Y Price Target
$1,042.13Price Target Upside39.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
Eli Lilly & Co News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceManagement reiterated strong confidence in both accelerating obesity franchise demand prospects and the company’s pipeline.
Market PositionOrforglipron's shorter timeline to market compared to AZD5004 suggests a competitive advantage for Eli Lilly.
Product DevelopmentMuvalaplin, Eli Lilly's oral Lp(a) candidate, demonstrated up to 85.8% reduction in Lp(a) levels in adults, which is competitive with injectable therapies.
Bears Say
Financial PerformanceLLY reported a miss driven by Mounjaro & Zepbound weakness, with a significant shortfall in their expected revenue.
Revenue GuidanceLLY lowered the top end of its revenue guidance, indicating potential challenges in meeting previous expectations.
Supply ChainPatients and prescribers may still see intermittent localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies.
---
Ownership Overview
10.35% Insiders
23.12% Mutual Funds
27.16% Other Institutional Investors
23.58% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LLY FAQ
What was Eli Lilly & Co’s price range in the past 12 months?
Eli Lilly & Co lowest stock price was $561.65 and its highest was $972.53 in the past 12 months.
What is Eli Lilly & Co’s market cap?
Currently, no data Available
When is Eli Lilly & Co’s upcoming earnings report date?
Eli Lilly & Co’s upcoming earnings report date is Jan 30, 2025 which is in 66 days.
How were Eli Lilly & Co’s earnings last quarter?
Eli Lilly & Co released its earnings results on Oct 30, 2024. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.421 by -$0.241.
Is Eli Lilly & Co overvalued?
According to Wall Street analysts Eli Lilly & Co’s price is currently Undervalued.
Does Eli Lilly & Co pay dividends?
Eli Lilly & Co pays a Quarterly dividend of $1.3 which represents an annual dividend yield of 0.67%. See more information on Eli Lilly & Co dividends here
What is Eli Lilly & Co’s EPS estimate?
Eli Lilly & Co’s EPS estimate is $5.47.
How many shares outstanding does Eli Lilly & Co have?
Eli Lilly & Co has 949,315,700 shares outstanding.
What happened to Eli Lilly & Co’s price movement after its last earnings report?
Eli Lilly & Co reported an EPS of $1.18 in its last earnings report, missing expectations of $1.421. Following the earnings report the stock price went down -6.281%.
Which hedge fund is a major shareholder of Eli Lilly & Co?
Among the largest hedge funds holding Eli Lilly & Co’s share is PRIMECAP Management Co. It holds Eli Lilly & Co’s shares valued at 16B.
---
Eli Lilly & Co Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,042.13 (39.32% Upside)
$1,042.13 (39.32% Upside)
Blogger Sentiment
Bullish
LLY Sentiment 85%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $47.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.51%
12-Months-Change
Fundamentals
Return on Equity
65.75%
Trailing 12-Months
Asset Growth
30.55%
Trailing 12-Months
Company Description
Eli Lilly & Co
Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is headquartered in Indianapolis, Indiana.
---
LLY Company Deck
---
LLY Earnings Call
Q3 2024
0:00 / 0:00
---
LLY Revenue Breakdown
84.44% Net product revenue
15.56% Collaboration and other revenue
---
LLY Stock 12 Month Forecast
Average Price Target
$1,042.13
▲(39.32% Upside)
Technical Analysis
Best Analysts Covering LLY
1 Year
1 Year Success Rate
32/37 ratings generated profit
1 Year Average Return
+35.73%
reiterated a buy rating 2 months ago
Copying Louise Chen's trades and holding each position for 1 Year would result in 86.49% of your transactions generating a profit, with an average return of +35.73% per trade.
---